Message from the Guest Editor

Dear Colleagues,

Immunohistochemistry is a pivotal tool allowing to quickly perform the diagnosis of many cancers, but also to establish the prognosis of some of them. More recently, IHC, through the use of new biomarkers, can be predictive of responsiveness of some targeted therapies. In this latter field, a couple of antibodies have been developed and can be routinely used to predict the efficiency of drugs targeting some genomic alterations; not only some mutations, but also some rearrangements. This Special Issue will highlight the current development of IHC in cancer: it will provide, i) a practical approach in the interpretation and immunohistochemical selection of lung/pleura-based neoplasms obtained from small biopsy and cytological samples, ii) the use of new predictive biomarkers which can provide results essential for timely and accurate therapeutic decision making in the era of the so called stratified medicine, iii) some algorithms using IHC for improvement of CUP diagnosis, and iv) the interest to get accreditation in IHC for a pathology laboratory to ensure a high quality level of the results.

Prof. Dr. Paul Hofman
Guest Editor

mdpi.com/si/11119
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

CiteScore (2018 Scopus data): 5.87, which equals rank 26/321 (Q1) in 'Oncology' and rank 24/191 (Q1) in 'Cancer Research'.

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI